期刊文献+

EGFR及耐药表型GST-π、P-gp、TopoⅡ在大肠癌组织中的表达及意义 被引量:4

下载PDF
导出
摘要 目的探讨表皮生长因子受体(EGFR)及耐药表型谷胱甘肽S-转移酶π(GST-π)、P-糖蛋白(P-gp)、DNA拓扑异构酶Ⅱ(TopoⅡ)在大肠癌组织中的表达及意义。方法采用免疫组化法检测190例大肠癌组织(大肠癌组)和20例正常大肠黏膜组织(对照组)中EGFR和GST-π、P-gp、TopoⅡ的表达情况;分析其与大肠癌临床病理参数的关系。结果 EGFR和GST-π、P-gp、TopoⅡ表达与肿瘤分化程度、淋巴结及远处转移有关(P均<0.05)。EGFR表达与GST-π、P-gp表达呈正相关。结论 EGFR在大肠癌组织中高表达;与多药耐药表型GST-π、P-gp的表达相关,可能参与了化疗耐药。针对EGFR的靶向治疗对化疗耐药、EGFR阳性患者有较好疗效。
出处 《山东医药》 CAS 2014年第10期88-90,共3页 Shandong Medical Journal
  • 相关文献

参考文献13

  • 1Chen L, Jiang B, Wang Z et al. Combined preoperative CEA and EGFR improves prognostic value in patients with stage I and stage II colorectal cancer [ J ]. Clin Transl Oncol, 2014, 16 ( 3 ) : 285- 292.
  • 2Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, et al. Erratum to:Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis-corre- lations with epidermal growth factor receptor, EGFR, focal adhe- sion kinase, and c-Met[J]. Tumour Biol, 2013,34(4) :2119.
  • 3范苗静,王林,曾韵洁,李海刚,沈溪明,林敏玲.EGFR在消化道肿瘤中的表达意义及其与GSTπ和c-Met的关系[J].广东医学,2009,30(3):432-434. 被引量:3
  • 4王齐敏,王莉芬,于香莉,秦华民,张文波,宋丽媛.胃癌组织中EGFR、C-erbB-2、TopoⅡα及P-gp的表达及意义[J].现代肿瘤医学,2013,21(4):834-837. 被引量:8
  • 5喻龙姗,张开光.MDR1在胃癌中的研究进展[J].国际消化病杂志,2012,32(6):363-365. 被引量:5
  • 6董丽娟,李红影.大肠癌组织中P-gP、GST-π、bcl-2的表达变化及意义[J].山东医药,2010,50(6):105-105. 被引量:7
  • 7Zhang KG, Qin CY, Wang HQ, et al. The effect of TRAIL on the expression of multidrug resistant genes MDR1, LRP and GST-π in drug-resistant gastric cancer cell SGC7901/VCR [ J ]. Hepatogastro enterology, 2012, 59(120) :2672-2676.
  • 8Campa D, Sainz J, Pardini B,et al. A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer [J]. PLoS One, 2012, 7 (3) :32784.
  • 9Vlachogeorgos GS, Manali ED, Blana E, et al. Placetal isoform glu- tathione S-transferase and P-glycoprotein expression in advanced nonsmall cell lung cancer: association with response to treatment and survival[J].Cancer,2008,114(6) :519-526.
  • 10Chikamori K, Grozav AG, Kozuki T, et al. DNA Topoisomerase II enzymes as molecular targets for cancer chemotherapy [ J ]. Curt Cancer Drug Targets,2010,10(7) :758-771.

二级参考文献52

  • 1魏学明,顾国利,任力,王石林,李德昌,宁守斌,熊梅.胃癌组织中多药耐药基因的表达特点及其对化疗的指导意义[J].胃肠病学和肝病学杂志,2009,18(11):988-992. 被引量:5
  • 2周清华,孙燕.加强我国肺癌分子靶向治疗基础和临床研究[J].中国肺癌杂志,2004,7(4):267-269. 被引量:51
  • 3Ling Yang.Incidence and mortality of gastric cancer in China[J].World Journal of Gastroenterology,2006,12(1):17-20. 被引量:344
  • 4周春华,孟庆勇.c-met及其相关蛋白与大肠癌关系的研究进展[J].现代实用医学,2006,18(8):605-607. 被引量:1
  • 5SAVAGE CR J R, HASH J H, COHEN S. Epidermal growth factor. Location of disulfide bonds[J]. J Biol Chem, 1973, 248 (22) : 7 669 -7 672.
  • 6BOONSTRA J, RIJKEN P, HUMBEL B, et al. The epidermal growth faetor[J]. Cell Biology. International, 1995,19 (5) : 413 -430.
  • 7TAMAS P, SOLTI Z, BAUER P, et al. Mechanism of epidermal growth factor regulation of Vav2, a guanine nucleotide exchange factor for rac[J]. J Biol Chem, 2003, 278(7): 5 163-5 171.
  • 8DOGRU ABBASOGLU S, MUTLU TURKOGLU U, TURKOGLU S, et al. Glutathione S - transferase - pi in malignant tissues and plasma of human colorectal and gastric cancers[ J ]. J Cancer Res Clin Oncol, 2002, 128(2) : 91 -95.
  • 9MOHAMMADZADEH G S, NASSERI MOGHADAM S, RASAEE M J, et al. Measurement of glutathione S - transferase and its classpi in plasma and tissue biopsies obtained after laparoscopy and endoscopy from subjects with esophagus and gastric cancer [ J]. Clin Biochem, 2003, 36(4) : 283 -288.
  • 10HERYNK M H, RADINSKY R. The coordinated functional expression of epidermal growth factor receptor and c - Met in colorectal carcinoma metastasis[J]. In Vivo, 2000, 14(5) : 587 -596.

共引文献33

同被引文献30

  • 1桂贤,刘会敏.肿瘤多药耐药发生机制的研究进展[J].上海医学,2005,28(2):161-164. 被引量:25
  • 2Rijpma S R, van den Heuvel J J, van der Velden M, et al. Atova- quone and quinine anti-malarials inhibit ATP binding cassette transporter activity[J]. Malar J, 2014,13:359.
  • 3Kirtane A R, Kalscheuer S M, Panyam J. Exploiting nanotechnol- ogy to overcome tumor drug resistance: Challenges and opportuni- ties[ J]. Adv Drug Deliv Rev, 2013,65 ( 13 - 14) : 1731 - 47.
  • 4De Iudicibus S, De Pellegrin A, Stocco G, et al. ABCB1 gene polymorphisms and expression of P-glycoprotein and long-term prognosis in colorectal cancer [ J ]. Anticancer Res, 2008, 28 (6B) :3921 -8.
  • 5Ding Z, Yang L, Xie X, et al. Expression and significance of hy- poxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells [ J ]. J Cancer Res Clin Oncol, 2010,136 ( 11 ) : 1697 - 707.
  • 6Morrow C S, Peklak-Scott C, Bishwokarma B, et al. Muhidrug re- sistance protein 1 ( MRP1, ABCC1 ) mediates resistance to mitox- antrone via glutathione-dependent drug efflux[ J]. Mol Pharmacol, 2006,69 (4) : 1499 - 505.
  • 7Roundhill E A, Burehill S A. Detection and characterisation of muhi-drug resistance protein 1 ( MRP-1 ) in human mitochondria [J]. Br J Cancer, 2012,106(6) :1224 -33.
  • 8Sinicrope FA, Rego RL. Prognostic impact of bim, puma, and noxa expression in human colon carcinomas [ J ]. Clin Cancer Res, 2008, 14(18) : 5810 -5818.
  • 9Maurer U, Charvet C. Glycogen synthase kinase - 3 regulates mi- tochondrial outerm embrane pemeabilization and apoptosis by des- tabolization of MCL - 1 [ J]. Mol Cell, 2006, 21 (6) : 749 - 760.
  • 10Mills JR, Hippo Y. mTORC1 promotes survival through transla- tional control of MCL- 1 [J]. Proc Natl Acad Sci U S A, 2008, 105(31) : 10853 - 10858.

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部